Cohen, OC;
Counsell, N;
Rabin, N;
Popat, R;
Owen, RG;
Popova, B;
Schofield, O;
... Yong, KL; + view all
(2019)
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
(5)
pp. 948-951.
10.1111/bjh.15649.
Preview |
Text
Clifton-Hadley_Cohen et al Letter.oc 28Aug2018.pdf - Accepted Version Download (485kB) | Preview |




Archive Staff Only
![]() |
View Item |